xemilofiban hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: xemilofiban hydrochloride
• 英文别名: [amino-[4-[[4-[[(3S)-5-ethoxy-5-oxopent-1-yn-3-yl]amino]-4-oxobutanoyl]amino]phenyl]methylidene]azanium;chloride
• 化学式: C₁₈H₂₂N₄O₄*ClH
• 分子量: 394.858
• InChiKey: JTZJXWLQRZUDFJ-BTQNPOSSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.18
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  134
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ethyl (3S)-amino-4-pentynoate hydrochloride 、 4-([4-(Aminoiminomethyl)phenyl]-amino)-4-oxobutanoic acid hydrochloride 在 N-甲基吗啉 、 氯甲酸异丁酯 作用下， 以70%的产率得到xemilofiban hydrochloride
  参考文献：
  名称：

  由L-天冬氨酸合成血小板聚集抑制剂xemilofiban。确认绝对配置

  摘要：

  已经由L-天冬氨酸合成西米洛非班（SC-54684A），总产率为18％，并且已经确认了绝对构型。

  DOI：

  10.1016/s0040-4039(98)00602-9

文献信息

• Substituted .beta.-amino acid derivatives useful as platelet aggregation
  申请人：Monsanto Company

  公开号：US05239113A1

  公开（公告）日：1993-08-24

  Novel substituted .beta. amino acid derivatives are provided which inhibit platelet aggregation and intermediates thereof. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.

  本发明提供了一种替代的新型.beta.氨基酸衍生物，能够抑制血小板聚集，以及其中间体。本发明还涉及制备这些衍生物的药物组合物和使用这些衍生物的方法。
• Process for the preparation of ethyl
  申请人：G. D. Searle & Co.

  公开号：US05536869A1

  公开（公告）日：1996-07-16

  The present invention relates to a novel process for the preparation of ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentyno ate and pharmaceutically acceptable acid addition salt thereof which comprises treating (trimethylsilyl)acetylene sequentially with n-butyllithium and 4-formylmorpholine followed by acid hydrolysis to give 3-(trimethylsilyl)-2-propynal; treating 3-(trimethylsilyl)-2-propynal with lithium bis(trimethylsilyl)amide to give in situ N,3-bis(trimethylsilyl)-2-propyn-1-imine; condensation of N,3-bis(trimethylsilyl)-2-propyn-1-imine with lithium t-butyl acetate to give (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate; treating (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate- with p-toluenesulfonic acid to give (.+-.)1,1-dimethylethyl 3-amino-5-(trimethylsilyl)-4-pentynoate, mono p-toluenesulfonic acid salt, treatment of resulting salt with ethanol in the presence of p-toluenesulfonic acid to give (.+-.)ethyl 3-amino-5-(trimethylsilyl)-4-pentynoate; desilylation of (.+-.)ethyl 3-amino-5-(trimethylsilyl)-4-pentynoate to give in situ (.+-.)ethyl 3-amino-4-pentynoate; resolution of (.+-.)ethyl 3-amino-4-pentynoate using (R)-(-)-mandelic acid and treatment of the resolved product with gaseous hydrochloric acid to give ethyl 3S-amino-4-pentynoate, monohydrochloride; coupling the ethyl 3S-amino-4-pentynoate, monohydrochloride to 4-[[4-(aminoiminomethyl)phenyl]amino]-4-oxobutanoic acid, monohydrochloride in the presence of isobutyl chloroformate and N-methylmorpholine to give ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentyno ate, monohydrochloride.

  本发明涉及一种新型制备乙基3S-[[4-[[4-(氨基亚甲基)苯基]氨基]-1,4-二氧戊基]氨基]-4-戊炔酸乙酯及其药学上可接受的酸加成盐的方法，该方法包括以下步骤：将（三甲基硅基）乙炔依次与正丁基锂和4-甲酰吗啉处理，然后进行酸水解以得到3-(三甲基硅基)-2-丙炔醛；将3-(三甲基硅基)-2-丙炔醛与双(三甲基硅基)胺锂处理以在位生成N,3-双(三甲基硅基)-2-丙炔-1-亚胺；将N,3-双(三甲基硅基)-2-丙炔-1-亚胺与叔丁基乙酸锂缩合以得到(.+-.)1,1-二甲基乙基3-氨基-5-(三甲基硅基)-4-戊炔酸乙酯；将(.+-.)1,1-二甲基乙基3-氨基-5-(三甲基硅基)-4-戊炔酸乙酯与对甲苯磺酸处理以得到(.+-.)1,1-二甲基乙基3-氨基-5-(三甲基硅基)-4-戊炔酸乙酯单对甲苯磺酸盐，将所得盐在对甲苯磺酸存在下与乙醇处理以得到(.+-.)乙基3-氨基-5-(三甲基硅基)-4-戊炔酸乙酯；去硅化(.+-.)乙基3-氨基-5-(三甲基硅基)-4-戊炔酸乙酯以在位生成(.+-.)乙基3-氨基-4-戊炔酸乙酯；使用(R)-(-)-苯基乙酸对(.+-.)乙基3-氨基-4-戊炔酸乙酯进行拆分，然后在气态盐酸存在下处理拆分产物以得到乙基3S-氨基-4-戊炔酸乙酯单盐酸盐；将乙基3S-氨基-4-戊炔酸乙酯单盐酸盐与4-[[4-(氨基亚甲基)苯基]氨基]-4-氧代丁酸单盐酸盐在异丙基氯甲酸酯和N-甲基吗啡存在下偶联以得到乙基3S-[[4-[[4-(氨基亚甲基)苯基]氨基]-1,4-二氧戊基]氨基]-4-戊炔酸乙酯单盐酸盐。
• Soft tissue implants and anti-scarring agents
  申请人：Hunter L. William

  公开号：US20050142162A1

  公开（公告）日：2005-06-30

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

  软组织植入物（例如乳房、胸肌、下巴、面部、唇部和鼻部植入物）与抗瘢痕剂结合使用，以抑制动物体内植入物放置时可能发生的瘢痕形成。
• Combination drug therapy for reducing scar tissue formation
  申请人：Afmedica, Inc.

  公开号：EP1844734A2

  公开（公告）日：2007-10-17

  The present invention describes various devices and methods wherein a cytostatic antiproliferative drug, either alone or in combination with other drugs, is placed between internal body tissues to prevent the formation of scar tissue and/or adhesions during healing of a wound or surgical site. Specific devices to achieve this administration include, but are not limited to, a permanent implant or a biodegradable material having an attached antiproliferative drug such as sirolimus. These antiproliferative drugs may be combined with other drugs including, but not limited to, antiplatelets, antithrombotics or anticoagulants. The present invention also contemplates methods to a reduce scar tissue and/or adhesions or adhesion formation at an anastomosis site. In particular, a cytostatic antiproliferative drug is administered to an arteriovenous shunt anastomoses in patients having end-stage renal disease.

  本发明描述了各种装置和方法，在这些装置和方法中，单独或与其他药物联合使用的细胞抑制性抗增生药物被放置在身体内部组织之间，以防止在伤口或手术部位愈合期间形成瘢痕组织和/或粘连。实现这种管理的具体装置包括但不限于永久性植入物或附有西罗莫司等抗增生药物的可生物降解材料。这些抗增殖药物可与其他药物结合使用，包括但不限于抗血小板、抗血栓或抗凝剂。本发明还考虑了减少吻合部位瘢痕组织和/或粘连或粘连形成的方法。特别是，对终末期肾病患者的动静脉分流吻合处施用细胞抑制性抗增生药物。
• RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT
  申请人：——

  公开号：US20020177172A1

  公开（公告）日：2002-11-28

  The invention provides a process to restore platelet aggregation by the administration of antibody combining site-containing molecules that specifically bind to a specific class of reversibly-bound GPIIb/IIIa fibrinogen receptor antagonist compounds.

  本发明提供了一种恢复血小板聚集的方法，即通过施用与特定类别的可逆结合 GPIIb/IIIa 纤维蛋白原受体拮抗剂化合物特异性结合的含抗体结合位点分子来恢复血小板聚集。